Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus

Frota, Ana Cristina Cisne; Harrison, Lee H.; Ferreira, Bianca; Menna-Barreto, Daniela; Castro, Raquel Bernardo Nana de; Silva, Giselle Pereira da; Oliveira, Ricardo Hugo de; Abreu, Thalita; Milagres, Lucimar G.; Hofer, Cristina Barroso

doi:10.1016/j.jped.2017.01.003

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among children aged 2–10 years with HIV infection and a CD4 percentage ≥25%, antibody titers against serogroup C waned substantially by 72 weeks after vaccination ( 169 ). Similar trends were observed subsequent to vaccination of HIV-infected children and adolescents with serogroup C meningococcal conjugate vaccine ( 170 – 173 ).…”

Section: Serogroups a C W And Y Meningococcal Vaccinessupporting

confidence: 67%

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Mbaeyi¹,

Bozio²,

Duffy³

et al. 2020

MMWR Recomm. Rep.

181

154

View full text Add to dashboard Cite

This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal vaccines. ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination with MenACWY for persons aged ≥2 months at increased risk for meningococcal disease caused by serogroups A, C, W, or Y, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor (e.g., eculizumab [Soliris] or ravulizumab [Ultomiris]); persons who have anatomic or functional asplenia; persons with human immunodeficiency virus infection; microbiologists routinely exposed to isolates of Neisseria meningitidis; persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroups A, C, W, or Y; persons who travel to or live in areas in which meningococcal disease is hyperendemic or epidemic; unvaccinated or incompletely vaccinated first-year college students living in residence halls; and military recruits. ACIP recommends MenACWY booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends routine use of MenB vaccine series among persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor; persons who have anatomic or functional asplenia; microbiologists who are routinely exposed to isolates of N. meningitidis; and persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroup B. ACIP recommends MenB booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends a MenB series for adolescents and young adults aged 16-23 years on the basis of shared clinical decision-making to provide short-term protection against disease caused by most strains of serogroup B N. meningitidis.

show abstract

Section: Serogroups a C W And Y Meningococcal Vaccinessupporting

confidence: 67%

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Mbaeyi¹,

Bozio²,

Duffy³

et al. 2020

MMWR Recomm. Rep.

181

154

View full text Add to dashboard Cite

show abstract

Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil

Frota

Ferreira

Harrison

et al. 2017

Vaccine

View full text Add to dashboard Cite

Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus

Abstract: Seroprotection at 12-18 months after single dose of MCC was low for both groups, and higher among individuals who presented baseline immunity. Among HIVI, vaccine should be administered after UVL is achieved.

Cited by 2 publications

References 22 publications

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil

Contact Info

Product

Resources

About